| Similar Articles |
|---|
 |
The Motley Fool
May 8, 2006
Stephen D. Simpson |
Cytyc Looking Toward New Tech It's worth paying attention to this women's health company's transition to new growth drivers. Investors, take note.   |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
Aspect Won't Put You to Sleep High valuation of this med-tech company all but guarantees that the stock will see some volatility. |
The Motley Fool
July 28, 2005
Stephen D. Simpson |
Respironics Still Breathes Freely Despite years of solid growth from Respironics, the respiratory market is still underserved and unappreciated. The history of the past few years would suggest you'll get another chance to buy these shares at a somewhat better valuation. |
The Motley Fool
November 15, 2005
Stephen D. Simpson |
Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note. |
The Motley Fool
August 18, 2005
Stephen D. Simpson |
Medtronic Keeps the Beat Strong growth in the ICD and spinal businesses keep Medtronic running. The stock is trading more or less at par to the market with respect to its P/E-to-growth ratio. Investors must decide for themselves whether that's a fair price to pay. |
The Motley Fool
May 24, 2006
Stephen D. Simpson |
Measuring Up Medtronic Everyone loves the med-tech firm. That makes it a dangerous investment. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
Cytyc Grows but Stays Focused Still concentrating on women's health, the company looks to move beyond its traditional diagnostics business. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
A Bard's Tale The advanced medical technology company's stock already reflects new products' potential. Still, life in the med-tech sector could get more interesting in the coming quarters. Investors, take note. |
The Motley Fool
July 27, 2006
Stephen D. Simpson |
Growth Ingrates Dump Intuitive Surgical Despite today's sell-off, Intuitive Surgical remains a red-hot grower in the med-tech space. |
The Motley Fool
May 24, 2007
Ryan Fuhrmann |
Chronic Healthiness at Medtronic The med-tech firm isn't growing as fast as it once was, but its fourth-quarter earnings report still managed to beat Wall Street's expectations. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
Don't Hold Your Breath for Kensey Nash It's not over for Kensey Nash -- it will soon be seeing revenue from new partners Medtronic and Zimmer. But the stock's price continues to value this company as a growing med-tech idea. |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry. |
The Motley Fool
August 21, 2006
Stephen D. Simpson |
Kensey Nash Losing the Benefit of the Doubt Med-tech investors won't wait indefinitely for growth. Investors can find better values in this sector if they're willing to roll up their sleeves for some due diligence. |
The Motley Fool
August 23, 2006
Stephen D. Simpson |
Is Medtronic Sweeping the Deck? Nothing's changing at a deep fundamental level in health care that would impede the growth of this giant med-tech corporation. However, investors need to proceed with caution. |
The Motley Fool
June 30, 2006
Stephen D. Simpson |
Arrow's Erratic Flight Progress for the med-tech is still slow in coming, though market rewards have come faster. Investors, take note. |
The Motley Fool
April 21, 2006
Stephen D. Simpson |
Bard Rolls On Nothing flashy here, but at the right price, this would be an interesting med-tech play. Investors, take note. |
The Motley Fool
October 31, 2005
Stephen D. Simpson |
Integra Needs to Grow From Within Acquired growth is nice, but organic growth is the key to long-term success. Quite frankly, the only way this stock works from a cash flow valuation standpoint is if the company does in fact deliver very good growth over the next 10 years or so. |
The Motley Fool
August 2, 2006
Stephen D. Simpson |
Integra the Cyborg Mediocre underlying growth is a cause for long-term concern at the med-tech company. Investors, take note. |
The Motley Fool
January 23, 2007
Ralph Casale |
Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note. |
